OncoSec Medical To Present at Four Events in June
May 27 2014 - 6:03AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will
present at four events in June. The company’s agenda includes a
number of high-profile scientific and investment conferences,
coming on the heels of their presentation of new clinical data at
the 2014 ASCO Annual Meeting. OncoSec’s June meeting itinerary is
as follows:
Boston Biotech Boston CEO
Punit Dhillon, President and CEO, will take part in a panel
discussion titled, “Alternative Business Models in Biotech”, at the
Boston Biotech Boston CEO Conference on June 5, 2014 at 11:45 pm
EST, at the Four Seasons Hotel in Boston, MA.
The Boston CEO Conference serves as a networking forum for
industry CEOs, venture capital and private equity leaders, and key
decision makers in the life sciences sector. Attendees gain
valuable insights from presentations and panel discussions
featuring CEOs from the world’s leading biopharmaceutical
companies. Boston Biotech hosts exclusive thought-leader forums for
senior bio-pharma executives. Each conference is highly interactive
and meant to facilitate discussion, information sharing,
networking, and corporate development among healthcare industry
leaders. For more information, please visit:
http://bbbiotechconference.com/conference-details.php?id=11
LD Micro 4th Invitational
Robert Pierce, M.D., Chief Medical Officer, will present a
corporate overview of the company at the LD Micro 4th Invitational
Conference, on June 4, 2014 at 1:00 pm PST, at the Luxe Hotel in
Los Angeles, CA.
LD MICRO is an investment newsletter firm that focuses on
finding undervalued companies in the micro-cap space. Since 2002,
the firm has published an annual list of recommended stocks, as
well as comprehensive reports on select companies throughout the
year. The 4th Invitational will feature company presentations and
facilitate 1-on-1 meetings between business leaders and investors,
as part of LD Micro’s ultimate goal of bringing out the finest
ideas in micro-cap and showcasing them to a tight-knit and loyal
investor base. For more information, please visit:
http://www.ldmicro.com
2014 BIO International Convention
Robert Pierce, M.D., Chief Medical Officer, will present an
overview of the company at the 2014 BIO International Convention,
as part of the BIO Business Forum, taking place June 23-26 at the
San Diego Convention Center in San Diego, California.
The BIO International Convention is the largest venue for
private company-to-company meetings in the world. According to an
independent survey, partnering events such as BIO drive the
majority of successful deals in the biopharma industry. This year’s
exhibition will feature more than 1700 exhibitors and host
thousands of organizations including leading biotech companies, top
25 pharma companies, top 20 CROs and CMOs, more than 300 academic
institutions including major research labs and government agencies
and the leading consultants and service companies. For more
information, please visit: http://convention.bio.org/2014/
4th European Post-Chicago Melanoma/Skin Cancer
Meeting
OncoSec representatives will attend and present at the 4th
European Post-Chicago Melanoma/Skin Cancer Meeting, hosted by the
European Association of Dermato Oncology (EADO). The meeting will
take place June 26-27, 2014 at the Leonardo Royal Hotel in Munich,
Germany.
The aim of the Interdisciplinary Global Conference on News in
Melanoma/Skin Cancer, which highlights results and interpretations
of ASCO 2014 presentations, is to grant a deep overall insight into
the development of new drugs for melanoma and other cutaneous
malignancies. EADO invites international key opinion leaders on
melanoma, non-melanoma skin cancers and cutaneous lymphomas to this
interactive meeting to give a comprehensive overview of new
developments in melanoma and other skin cancers. This high-profile
event allows the world’s leading experts in these fields to
directly communicate with attendees through specified presentations
and discussions on the latest clinical trial results and exciting
new therapeutics. For more information, please visit:
http://www.melanomaglobal2014.org
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma
respectively
(http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search).
As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination-based approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Veronica Vallejo, CFO,
855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024